PRIORITY LIST Medicines and health innovations for which voluntary licensing and/or technology transfer through MPP would lead to expanded access, significant health benefits, and substantial public health impact compared to standards of care
avoiding high-fat foods during escalation), hydration, and pacing adjustments that may help reduce gastrointestinal discomfort
There may be moderate side effects, such as mild discomfort at the injection site
J Inherit Metab Dis 35(3):381398 Rosa AP, Jacques CE, Moraes TB, Wannmacher CM, Dutra AM, Dutra-Filho CS (2012) Phenylpyruvic acid decreases glucose-6-phosphate dehydrogenase activity in rat brain
What the Clinical Data Says About Extended Treatment The backbone of everything we know about extended Retatrutide use comes from the Phase 2 SURMOUNT-1 trial, which tracked 338 participants across multiple dose groups for a full 48 weeks